Impact of Government Cuts on Biotech

Recent cuts across government health agencies have raised concerns within the biotech sector, particularly regarding the FDA and its ability to conduct drug manufacturing inspections. The device division faced more severe reductions, primarily affecting probationary staff, which was concerning given the existing backlog of inspections exacerbated by prior staff shortages. The uncertainty around how these layoffs will influence biotech operations remains prevalent, as most drug-focused inspectors appear to be relatively unscathed. As the situation evolves, stakeholders are left questioning the long-term ramifications on drug reviews and interactions with biotech companies.